Firm announcement – No. 10 / 2025
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Copenhagen, Denmark, April 19, 2025 – Zealand Pharma A/S (“the Firm” or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology firm centered on the invention and improvement of modern peptide-based medicines, has acquired info on transactions in Zealand Pharma’s shares or related securities performed by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the knowledge on such transactions.
Please see the connected file(s).
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) is a biotechnology firm centered on the invention and improvement of peptide-based medicines. Greater than 10 drug candidates invented by Zealand have superior into medical improvement, of which two have reached the market and three candidates are in late-stage improvement. The corporate has improvement partnerships with numerous blue-chip pharma corporations in addition to business partnerships for its marketed merchandise.
Zealand was based in 1998 and is headquartered in Copenhagen, Denmark, with a presence in america. For extra details about Zealand’s enterprise and actions, please go to www.zealandpharma.com.
Contact
Adam Lange (Traders)
Vice President, Investor Relations
Zealand Pharma
E mail: alange@zealandpharma.com
Neshat Ahmadi (Traders)
Investor Relations Supervisor
Zealand Pharma
E mail: neahmadi@zealandpharma.com
Anna Krassowska, PhD (Traders and Media)
Vice President, Investor Relations & Company Communications
Zealand Pharma
E mail: akrassowska@zealandpharma.com
- 19042025 – PDMR transactions_Final
Source link
#Transactions #Zealand #Pharma #shares #andor #related #securities #persons #discharging #managerial #responsibilities #andor #closely #persons
